Does Ozempic cause heart rhythm problems? What 30 trials found

If your heart feels like it is racing or fluttering after you start Ozempic, you are not the only one reaching for your phone to search it. The fear behind that search is real: could a weight-loss drug be nudging your heart into a dangerous rhythm? A 2025 review pooled 30 randomised trials and 32,490 people to look at exactly that question, and the answer is more reassuring than the headlines suggest - with a few honest limits worth knowing.

The short version

In 30 trials of semaglutide covering 32,490 people with type 2 diabetes, atrial fibrillation was 27% less common on the drug than on placebo (RR 0.73), not more common. Semaglutide also lowered complete heart block and death from cardiovascular causes. It did not change heart attack, stroke, or heart failure rates. These were diabetes trials, so the numbers may not map perfectly onto someone taking Wegovy for weight loss alone.

Why do so many people worry about their heart on Ozempic?

The worry has a real trigger. Semaglutide and the other GLP-1 medications nudge your resting heart rate up, usually by about 2 to 4 beats per minute on average. That is a small shift, and many people never feel it, but some do. A heart that beats a little faster, or that seems to skip, can feel alarming when you are already watching closely for side effects.

That physical sensation is what sends people searching for "Ozempic heart palpitations" or "does semaglutide cause AFib." The useful question is not whether your pulse ticks up a few beats. It is whether that faster rate turns into an actual rhythm disorder like atrial fibrillation, the most common serious arrhythmia. That is the gap this analysis set out to fill.

What 30 trials found about semaglutide and heart rhythm

The review, published in Frontiers in Endocrinology in 2025, gathered every randomised trial it could find that recorded rhythm events, then pooled the numbers. Across 32,490 patients with type 2 diabetes, the arrhythmia signal pointed toward protection rather than harm.

Atrial fibrillation, the flutter most people are afraid of, was 27% less likely on semaglutide (RR 0.73, 95% CI 0.54 to 0.98). Complete AV block, a serious stall in the heart's electrical wiring, dropped sharply (RR 0.22, 95% CI 0.06 to 0.80). It is a rare event, though, so that estimate carries a wide margin of uncertainty.

Not every rhythm outcome was reassuring in the same way. Ventricular tachycardia, a fast rhythm arising from the heart's lower chambers, landed at RR 1.77, a number above 1. But its confidence interval (0.71 to 4.39) was so wide it cannot rule anything in or out. There simply were not enough of those events to draw a conclusion. The honest reading is no clear signal of ventricular harm, but no clean all-clear either.

Here is how the main rhythm outcomes lined up, all versus placebo or control:

Rhythm outcome	Risk vs control (RR)	What it means
Atrial fibrillation	0.73 (0.54-0.98)	27% lower, statistically clear
Complete AV block	0.22 (0.06-0.80)	Sharply lower, but a rare event
Ventricular tachycardia	1.77 (0.71-4.39)	Too few events to judge
Atrial flutter	0.88 (0.36-2.16)	No clear difference

Oral pills showed a bigger rhythm benefit than injections

When the researchers split the trials by formulation, oral semaglutide showed a larger drop in atrial fibrillation (RR 0.49) than the weekly injection (RR 0.80). Why the pill would edge out the shot here is not settled, and the oral trials were fewer, so treat this as an early signal rather than a reason to switch anything. If you want the wider heart data on the pill, we cover it in the SOUL trial on oral semaglutide and heart attack risk.

The bigger heart picture: what changed and what did not

Rhythm was only one part of what these trials tracked. On the outcomes people fear most, the results were mixed in a way worth stating plainly.

Death from cardiovascular causes was 24% lower on semaglutide (RR 0.76), and the need for procedures to reopen blocked arteries fell by 32% (RR 0.68). Those are meaningful. But heart attacks (RR 0.86), strokes (RR 0.83), and heart failure (RR 1.01) showed no statistically clear change in this pooled analysis. So this is not a "semaglutide prevents heart attacks" story. It is a rhythm-and-survival story, and those are not the same claim.

That fits the larger evidence base rather than rewriting it. The SELECT trial showed semaglutide's heart benefits held even independent of weight loss, and heart failure has its own nuances that we unpack in a separate review of 22,000 HFpEF patients. One meta-analysis does not overturn those findings. It adds the rhythm layer that had been missing.

What this does and does not tell you

Three limits matter before you take these numbers to the bank. First, every patient in these trials had type 2 diabetes. If you take Wegovy or Ozempic purely for weight loss with normal blood sugar, the rhythm findings are reassuring but not a direct match to your situation. Second, several outcomes rested on a small number of events, which is why the confidence intervals on things like complete AV block are so wide. Third, the trials were not designed mainly to hunt for arrhythmias, so rhythm events were logged as side effects rather than caught with continuous monitoring.

One more boundary: this analysis was semaglutide only. It says nothing about tirzepatide, the ingredient in Mounjaro and Zepbound. For that drug's separate heart story, see our piece on whether Mounjaro protects your heart.

How to protect your heart rhythm on GLP-1 medications

Here is the part within your control. The most plausible way a GLP-1 drug tips someone into a rhythm problem is not a direct electrical effect on the heart. It is dehydration and mineral loss from the gut side effects - the nausea, vomiting, and diarrhoea that hit hardest in the first weeks and around each dose increase. Low magnesium and low potassium are well-documented arrhythmia triggers, and both drop fast when you are eating little and losing fluid.

• Replace fluids on a schedule, not just when thirsty. GLP-1 drugs blunt appetite and thirst together, so it is easy to slide into dehydration without noticing.
• Watch magnesium and potassium. Vomiting and diarrhoea strip both minerals. Food comes first - leafy greens, beans, nuts, potatoes, bananas - and a magnesium supplement can help close the gap if your intake is low.
• Do not brush off new palpitations that come with dizziness. A slightly faster resting pulse is expected. A pounding, irregular beat paired with lightheadedness or breathlessness is not, and we cover that combination in our guide to GLP-1 dizziness and vertigo. It is a reason to call your prescriber.
• Keep your prescriber informed if you already have AFib. The group-level data is reassuring, but an existing rhythm condition deserves an individual plan, not a population average.

Eating a fraction of what you used to means fewer of the minerals your heart's electrical system runs on. That gap is the idea behind GLP-1 Shield - the nutrients most likely to run short on a GLP-1 medication, magnesium among them, in one place, so the basics your heart and muscles depend on stay covered while you lose the weight.

Frequently asked questions

Does Ozempic cause heart palpitations?

Ozempic can make your heart beat a little faster. Semaglutide raises resting heart rate by roughly 2 to 4 beats per minute on average, which some people feel as palpitations. In a 2025 meta-analysis of 30 trials and 32,490 people with type 2 diabetes, that faster rate did not translate into more atrial fibrillation - AFib was actually 27% less common. New palpitations with dizziness still warrant a call to your prescriber.

Can you take Ozempic if you have atrial fibrillation?

There is no blanket rule against it, and the trial data is reassuring: in a 2025 review of 32,490 people with type 2 diabetes, semaglutide was linked to 27% less atrial fibrillation, not more. But an existing rhythm condition needs an individual plan. Anyone with diagnosed AFib should confirm the decision with the doctor managing their heart, rather than rely on a group average.

Does semaglutide raise your heart rate?

Yes, modestly. Semaglutide and other GLP-1 medications raise resting heart rate by about 2 to 4 beats per minute on average, a well-documented class effect. For most people this small rise is not dangerous, and the same 2025 meta-analysis found lower rates of atrial fibrillation and cardiovascular death on the drug. A large or sustained jump in heart rate is worth reporting to your prescriber.

Does Ozempic weaken your heart?

The evidence points the other way for most people. In the 2025 meta-analysis, semaglutide lowered cardiovascular death by 24% and the need to reopen blocked arteries by 32%, with no rise in heart failure (RR 1.01). It did not clearly reduce heart attacks or strokes, so it is not a cure-all, but "weakens the heart" is not what the pooled trial data shows.